Related Experiment Video
Updated: Apr 16, 2026

12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
15.4K
Persistent major molecular response to nilotinib therapy in a patient with chronic myeloid leukemia harboring ABL
Jinyi Zhou1, Qi Qu1, Suning Chen1
1a Jiangsu Institute of Hematology, Collaborative Innovation Center of Hematology, Key laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University , Suzhou , Jiangsu Province, 215006 , PR China.
Leukemia & Lymphoma
|February 28, 2015
Abstract
No abstract available in PubMed .
Related Concept Videos
Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K
Combination Therapies and Personalized Medicine
6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Treatment Resistent Cancers
1.5K
1.5K

